Drug-induced Adverse Events
Renal manifestations of recreational drugs: A narrative review of the literature
Medicine (Baltimore). 2022 Dec 16;101(50):e31888. doi: 10.1097/MD.0000000000031888.
NO ABSTRACT
PMID:36550840 | DOI:10.1097/MD.0000000000031888
LiSA: an assisted literature search pipeline for detecting serious adverse drug events with deep learning
BMC Med Inform Decis Mak. 2022 Dec 22;22(1):338. doi: 10.1186/s12911-022-02085-0.
ABSTRACT
INTRODUCTION: Detecting safety signals attributed to a drug in scientific literature is a fundamental issue in pharmacovigilance. The constant increase in the volume of publications requires the automation of this tedious task, in order to find and extract relevant articles from the pack. This task is critical, as serious Adverse Drug Reactions (ADRs) still account for a large number of hospital admissions each year.
OBJECTIVES: The aim of this study is to develop an augmented intelligence methodology for automatically identifying relevant publications mentioning an established link between a Drug and a Serious Adverse Event, according to the European Medicines Agency (EMA) definition of seriousness.
METHODS: The proposed pipeline, called LiSA (for Literature Search Application), is based on three independent deep learning models supporting a precise detection of safety signals in the biomedical literature. By combining a Bidirectional Encoder Representations from Transformers (BERT) algorithms and a modular architecture, the pipeline achieves a precision of 0.81 and a recall of 0.89 at sentences level in articles extracted from PubMed (either abstract or full-text). We also measured that by using LiSA, a medical reviewer increases by a factor of 2.5 the number of relevant documents it can collect and evaluate compared to a simple keyword search. In the interest of re-usability, emphasis was placed on building a modular pipeline allowing the insertion of other NLP modules to enrich the results provided by the system, and extend it to other use cases. In addition, a lightweight visualization tool was developed to analyze and monitor safety signal results.
CONCLUSIONS: Overall, the generic pipeline and the visualization tool proposed in this article allows for efficient and accurate monitoring of serious adverse drug reactions from the literature and can easily be adapted to similar pharmacovigilance use cases. To facilitate reproducibility and benefit other research studies, we also shared a first benchmark dataset for Serious Adverse Drug Events detection.
PMID:36550485 | PMC:PMC9773506 | DOI:10.1186/s12911-022-02085-0
Levofloxacin-associated transient mixed sensorimotor lacunar syndrome
BMJ Case Rep. 2022 Dec 22;15(12):e252052. doi: 10.1136/bcr-2022-252052.
ABSTRACT
Fluoroquinolones are commonly used antimicrobials with multiple known adverse effects, yet overdose events are rarely reported. Here, we report a case of a previously healthy middle-aged woman who unintentionally ingested 7 g of levofloxacin in one dose. Thereafter, she presented to the emergency department with hemiparesis concerning for ischaemic stroke and was administered tissue plasminogen activator. Her brain imaging showed no ischaemic injury and her symptoms resolved within 24 hours; this is consistent with a transient ischaemic attack. Our case highlights potential adverse effects of an acute overdose of levofloxacin that has not previously been well described.
PMID:36549757 | DOI:10.1136/bcr-2022-252052
Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis
BMJ Open. 2022 Dec 22;12(12):e061476. doi: 10.1136/bmjopen-2022-061476.
ABSTRACT
OBJECTIVES: To assess the risk of new-onset or worsening hyperglycaemia, hypertension, weight gain and hyperlipidaemia with systemic corticosteroid therapy (CST) as reported in published randomised control trial (RCT) studies.
DATA SOURCES: Literature search using MEDLINE, EMBASE, Cochrane library, Web of Science and Scopus STUDY ELIGIBILITY CRITERIA: Published articles on results of RCT with a systemic CST arm with numerical data presented on adverse effect (AE).
PARTICIPANTS AND INTERVENTIONS: Reports of hyperglycaemia, hypertension, weight gain and hyperlipidaemia associated with systemic CST in patients or healthy volunteer's ≥17 years of age.
STUDY APPRAISAL METHODS: Risk of bias tool, assessment at the level of AE and key study characteristics.
RESULTS: A total of 5446 articles were screened to include 118 studies with 152 systemic CST arms (total participants=17 113 among which 8569 participants treated with CST). Pooled prevalence of hyperglycaemia in the CST arms within the studies was 10% (95% CI 7% to 14%), with the highest prevalence in respiratory illnesses at 22% (95% CI 9% to 35%). Pooled prevalence of severe hyperglycaemia, hypertension, weight gain and hyperlipidaemia within the corticosteroid arms was 5% (95% CI 2% to 9%), 6% (95% CI 4% to 8%), 13% (95% CI 8% to 18%), 8% (95% CI 4% to 17%), respectively. CST was significantly associated hyperglycaemia, hypertension and weight gain as noted in double-blinded placebo-controlled parallel-arms studies: OR of 2.13 (95% CI 1.66 to 2.72), 1.68 (95% CI 0.96 to 2.95) and 5.20 (95% CI 2.10 to 12.90), respectively. Intravenous therapy posed higher risk than oral therapy: OR of 2.39 (95% CI 1.16 to 4.91).
LIMITATIONS: There was significant heterogeneity in the AE definitions and quality of AE reporting in the primary studies and patient populations in the studies. The impact of cumulative dose effect on incidental AE could not be calculated.
CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS: Systemic CST use is associated with increased risk of metabolic AEs, which differs for each disease group and route of administration.
PROSPERO REGISTRATION NUMBER: CRD42020161270.
PMID:36549729 | PMC:PMC9772659 | DOI:10.1136/bmjopen-2022-061476
Chinese herbal compound prescriptions combined with Chinese medicine powder based on traditional Chinese medicine syndrome differentiation for treatment of chronic atrophic gastritis with erosion: a multi-center, randomized, positive-controlled...
Chin Med. 2022 Dec 22;17(1):142. doi: 10.1186/s13020-022-00692-7.
NO ABSTRACT
PMID:36550503 | DOI:10.1186/s13020-022-00692-7
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data
Oncology (Williston Park). 2022 Dec 20;36(12):732-738. doi: 10.46883/2022.25920981.
NO ABSTRACT
PMID:36548097 | DOI:10.46883/2022.25920981
Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS
Ther Adv Drug Saf. 2022 Dec 16;13:20420986221143266. doi: 10.1177/20420986221143266. eCollection 2022.
NO ABSTRACT
PMID:36545565 | PMC:PMC9761248 | DOI:10.1177/20420986221143266
Drug-related Death low Registration in Iran: A Mixed Method Approach for Causes, Recommendations to Solve This Problem and Geographical Evaluation of an Intervention
Addict Health. 2022 Apr;14(2):138-151. doi: 10.22122/AHJ.2022.196156.1266.
NO ABSTRACT
PMID:36544515 | PMC:PMC9743819 | DOI:10.22122/AHJ.2022.196156.1266
Toxocarosis: a One Health issue
Drug Ther Bull. 2023 Jan;61(1):3. doi: 10.1136/dtb.2022.000072.
NO ABSTRACT
PMID:36543344 | DOI:10.1136/dtb.2022.000072
Safety update: dupilumab and ocular adverse reactions
Drug Ther Bull. 2023 Jan;61(1):6. doi: 10.1136/dtb.2022.000073.
NO ABSTRACT
PMID:36543342 | DOI:10.1136/dtb.2022.000073
Escitalopram Induced Angioedema
Cureus. 2022 Nov 17;14(11):e31600. doi: 10.7759/cureus.31600. eCollection 2022 Nov.
NO ABSTRACT
PMID:36540519 | PMC:PMC9758958 | DOI:10.7759/cureus.31600
Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects
Nat Commun. 2022 Dec 20;13(1):7838. doi: 10.1038/s41467-022-35470-4.
NO ABSTRACT
PMID:36539421 | PMC:PMC9767940 | DOI:10.1038/s41467-022-35470-4
Determination and comparison of potential drug-drug interactions using three different databases in northern cyprus community pharmacies
Niger J Clin Pract. 2022 Dec;25(12):2005-2009. doi: 10.4103/njcp.njcp_448_22.
NO ABSTRACT
PMID:36537458 | DOI:10.4103/njcp.njcp_448_22
Adverse drug reactions of itolizumab in COVID-19 patient: A case report
Indian J Pharmacol. 2022 Sep-Oct;54(5):377-378. doi: 10.4103/ijp.ijp_803_21.
NO ABSTRACT
PMID:36537408 | DOI:10.4103/ijp.ijp_803_21
Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience
Indian J Pharmacol. 2022 Sep-Oct;54(5):349-352. doi: 10.4103/ijp.ijp_844_21.
NO ABSTRACT
PMID:36537404 | DOI:10.4103/ijp.ijp_844_21
Successful treatment of switching from benzodiazepine to orexin receptor antagonists improves cognitive function in psychiatric disorders: four case reports
Int Clin Psychopharmacol. 2022 Dec 16. doi: 10.1097/YIC.0000000000000450. Online ahead of print.
NO ABSTRACT
PMID:36539372 | DOI:10.1097/YIC.0000000000000450
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors
Invest New Drugs. 2022 Dec 20. doi: 10.1007/s10637-022-01319-2. Online ahead of print.
NO ABSTRACT
PMID:36538259 | DOI:10.1007/s10637-022-01319-2
Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19
Pharmacol Res Perspect. 2023 Feb;11(1):e01036. doi: 10.1002/prp2.1036.
NO ABSTRACT
PMID:36537346 | DOI:10.1002/prp2.1036
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <em>EGFR</em> exon 20 insertion–positive non–small cell lung cancer
Expert Rev Anticancer Ther. 2022 Dec 20. doi: 10.1080/14737140.2023.2157815. Online ahead of print.
NO ABSTRACT
PMID:36537204 | DOI:10.1080/14737140.2023.2157815
Liver injury induced by COVID 19 treatment - what do we know?
World J Gastroenterol. 2022 Dec 7;28(45):6314-6327. doi: 10.3748/wjg.v28.i45.6314.
NO ABSTRACT
PMID:36533104 | PMC:PMC9753058 | DOI:10.3748/wjg.v28.i45.6314